Management of Immunotherapy-Related Endocrinopathies

Missy Grier, MSN, APRN, ACNS-BC


In the past several years, the field of immuno-oncology has exploded. Checkpoint inhibitors (PD-1, PD-L1, CTLA-4), chimeric antigen receptor (CAR) T-cell therapy, and monoclonal antibodies can add years to the lives of patients with certain malignancies. But to add quality to those years, advanced practice nurses must be able to recognize and treat immune-related adverse effects (irAEs).

View Article @

ONS Articles

Dive into a rich source of oncology nursing expertise with ONS articles.

View All Articles

Related Topics